Prevalence of dysglycemia and associated risk factors in patients with pancreatic benign and low-grade malignant tumors before pancreatic surgery: A prospective observational study

Jie Yang†, Jia Zhang†, Rui Wang†, Ya Liu† and Yonghua Chen‡

†Department of Pancreatic Surgery, West China Hospital of Sichuan University, Chengdu, China
‡Department of Breast Surgery, West China Hospital of Sichuan University, Chengdu, China

Background: Pancreatic benign and low-grade malignant tumors (PBLMT) have experienced a rapid increase in incidence rates worldwide. Few studies have focused on the glucose metabolism status of patients with PBLMT before pancreatic surgery.

Methods: From August 2017 to June 2018, 70 patients with PBLMT were prospectively screened for abnormalities in glucose metabolism by an oral glucose tolerance test (OGTT) before pancreatic surgery. Patients were classified as having normal glucose tolerance (NGT), prediabetes mellitus (pre-DM), or new-onset DM (NOD) according to the American Diabetes Association (ADA) criteria. Glucose metabolism indices were calculated based on the OGTT parameters. Tumor volume and remnant pancreatic volume (RPV) were measured by computed tomography.

Results: Forty-nine of 70 patients with PBLMT developed dysglycemia (pre-DM and NOD). RPV was smaller in the pre-DM (57.44 ± 18.20 cm³ vs. 70.48 ± 14.08 cm³, P = 0.001) and NOD groups (37.38 ± 20.40 cm³ vs. 70.48 ± 14.08 cm³, P < 0.001) than in the NGT group. The homeostasis model assessment of β-cell function (HOMA2-β), insulinogenic index (IGI), and insulin secretion/insulin resistance index (ISSI-2) were worse in the pre-DM and NOD groups compared with NGT group (all P < 0.05). After univariate and multivariate analyses, age over 60 years (P = 0.049, OR = 5.76, 95% CI: 1.01-32.92) and RPV less than 49.36 cm³ (P = 0.024, OR = 8.59, 95% CI: 1.34-55.22) were recognized as independent risk factors for dysglycemia. The analysis of all patients revealed inverse correlations between RPV and both in age (r = -0.28, P = 0.019) and tumor volume (r = -0.28, P = 0.032). Positive correlations were found between RPV and both IGI (r = 0.29, P = 0.019) and ISSI-2 (r = 0.39, P = 0.0011).
Conclusion: In patients with PBLMT, 70% had dysglycemia before surgery. Old age and a reduction in RPV were independent risk factors for developing dysglycemia before pancreatic surgery. The decisions to treat PBLMT with resection should hinge more on the risk of dysglycemia as well as potential malignancy.

KEYWORDS
diabetes mellitus, pancreatic tumors, pancreatic endocrine function, remnant pancreatic volume, risk factors

Introduction

Pancreatic benign and low-grade malignant tumors (PBLMT), such as the serous or mucinous cystic tumors, intraductal papillary mucinous tumors (IPMN), solid pseudopapillary tumors, and pancreatic neuroendocrine tumors (PNET), have been acknowledged worldwide for their rapid growth in incidence rate (1, 2). Treatment of PBLMT with partial pancreatectomy or organ-preserving pancreatic surgery could preserve the pancreas parenchyma and exocrine and endocrine functions (3, 4). However, patients suffering from these pancreatic tumors might develop diabetes mellitus (DM) before and after pancreatic surgery. Pancreatogenic DM accounts for approximately 8% of patients with diabetes in Western countries, with chronic pancreatitis and pancreatic cancer currently recognized as the first two causes (5, 6). Pancreatic tumors can alter endocrine and metabolic conditions before and after surgery (7). Research has indicated an epidemic of DM in patients with PBLMT after pancreatic surgery, albeit at a lower rate than in patients with chronic pancreatitis (8, 9). Indeed, few studies have focused on the glucose metabolism status of PBLMT patients. The prevalence of DM and impaired fasting glucose was 24.4% in PNET patients who did not receive medical treatment (10). Based on a meta-study, the prevalence of new-onset DM in IPMN patients was 6% (68 of 1,202) with a range of 1.5% to 29% (11). However, the lack of a clear definition or the use of fasting plasma glucose levels alone might not accurately evaluate the glycemic traits of PBLMT patients.

With the present study, we sought to provide prospective insight into the actual glucose metabolism condition in patients with PBLMT by an oral glucose tolerance test (OGTT) before pancreatic surgery. Furthermore, we explored the risk factors for the PBLMT patients, especially involving the tumor volume and remnant pancreatic volume.

Methods

Study design

From August 2017 to June 2018, 80 patients with suspected PBLMT were prospectively screened for abnormalities in glucose metabolism before pancreatic surgery. We excluded six patients previously diagnosed with DM, three pathologically diagnosed with functional neuroendocrine tumors, and one with IPMN-developed ductal adenocarcinoma. The remaining 70 participants were included in the analysis (Figure 1 and Supplementary Table 1). The study was approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee (2014 Trail No.37) and conformed to the Declaration of Helsinki. Informed consent was acquired from all individual participants and guardians included in the study.

Biochemical parameters

Subjects were evaluated at West China Hospital after at least an 8-hour overnight fast before surgery. A 3-hour oral glucose tolerance test (OGTT) was performed with a 75-g glucose load. Blood samples were collected at 0, 30-, 60-, 120-, and 180-min time points, and each sample’s plasma glucose, insulin, and C-peptide concentrations were tested. Meanwhile, HbA1c was measured. Patients were classified as having normal glucose tolerance (NGT, fasting plasma glucose < 5.6 mmol/L and 2-hour plasma glucose < 7.8 mmol/L), prediabetes mellitus (pre-DM, fasting plasma glucose 5.6-6.9 mmol/L and/or 2-hour plasma glucose 7.8-11 mmol/L), or new-onset DM (NOD, fasting plasma glucose ≥ 7 mmol/L and/or 2-hour plasma glucose ≥ 11.1 mmol/L), according to the American Diabetes Association (ADA) criteria (12).

The areas under the curve of glucose (AUCglucose), insulin (AUCinsulin), and C-peptide (AUCC-peptide) were calculated using trapezoidal integration from 0 to 180 min. The homeostasis model assessment of insulin resistance (HOMA2-IR) or β-cell function (HOMA2-β) was calculated from fasting glucose and insulin levels as previously described (13). The Matsuda index was adopted as a measure of insulin sensitivity (14). To evaluate β-cell function corrected for the degree of insulin sensitivity, two surrogate measures were adopted in this study: 1) insulinogenic index (IGI), which was calculated by the ratio of 30 min insulin minus fasting insulin to 30 min glucose minus fasting glucose (ΔInsulin30:ΔGlucose30) (15), was validated against first-phase
insulin secretion on intravenous glucose tolerance testing, and 2) insulin secretion/insulin resistance index (ISSI-2, or disposition index) was calculated by IGI multiplied by the Matsuda index (15).

Carbohydrate antigen 19-9 (CA 19-9), total bilirubin, alanine transaminase, albumin, triglyceride, cholesterol, high-density lipoprotein, low-density lipoprotein, beta-hydroxybutyrate, and total bile acids were measured in the laboratory department of West China Hospital of Sichuan University according to national standards.

Remnant pancreatic volume and tumor volume

Abdominal computed tomography (CT) scans were used to analyze the remnant pancreatic volume (RPV) as described previously (16, 17). The pancreas was identified on each image, and the outline of normal pancreatic tissue, which excluded the tumor region, was annotated by freehand region estimation to generate a pancreatic area for each slice. Pancreatic volume was calculated by multiplying the estimated area of pancreatic tissue on each image slice by the interval between slices. The tumor volume of each patient was calculated through the same procedure as RPV, and both were assessed independently by two authors (JY and JZ). RPV and tumor volume were classified by thirds of the distribution in the logistic regression analysis.

Statistical analysis

All the data were analysed by the SPSS version 24.0 (IBM, New York, US). Data are presented as frequencies for categorical variables and mean ± standard deviation (SD) for continuous variables. Differences between groups were analysed using the independent samples t test, Mann–Whitney U nonparametric test for continuous data, and Pearson’s chi-square test for categorical data. We used univariate and multivariate logistic regression models to compute the odds ratio (OR) with a 95% confidence interval (CI) estimate of relative risk. Correlations were determined using Pearson’s correlation coefficient as appropriate. A two-sided P value less than 0.05 was regarded as statistically significant.

Results

Characteristics of patients

Of the included 70 PBLMT patients, 43 were pathologically diagnosed with pancreatic cystic tumors, 14 were diagnosed with solid pseudopapillary tumors, and 13 were nonfunctional neuroendocrine tumors. Preoperative OGTT revealed that the prevalence of NGT, pre-DM, and NOD was 30%, 55.7%, and 14.3%, respectively. Table 1 presents the characteristics of patients with different glucose tolerance statuses. Patients with NGT were younger than pre-DM and NOD (\(P = 0.002\) and \(P = 0.001\), respectively). Patients in the NGT group had the highest HbA1c levels (6.65 ± 0.78%), compared with the pre-DM group (5.77 ± 0.32%, \(P = 0.015\)) and the NGT group (5.29 ± 0.21%, \(P = 0.002\)). HbA1c level was higher in the pre-DM group than in the NGT group (\(P < 0.001\)). The median tumor volume of all involved patients was 11.50 cm³ (range from 0.09 to 216.97 cm³). Tumor volume did not differ between NGT (24.28 ± 32.05 cm³) and pre-DM (22.89 ± 35.61 cm³) patients (\(P = 0.882\)); however, both were smaller than that in NOD patients (64.69 ± 74.12 cm³, \(P = 0.041\) and \(P = 0.049\), respectively). The median RPV was 58.67 cm³ (range from 7.50 to 91.93 cm³) in all patients. RPV was smaller in pre-DM (57.44 ± 18.20 cm³ vs.
TABLE 1 Characteristics of PBLMT patients with different glucose tolerance statuses.

| Characteristics                  | NGT (n = 21) | Pre-DM (n = 39) | NOD (n = 10) | P value 1 | P value 2 | P value 3 |
|----------------------------------|--------------|-----------------|--------------|-----------|-----------|-----------|
| Sex (female)                     | 17           | 22              | 9            | 0.088     | 0.575     | 0.130     |
| Age (year)                       | 42.1 ± 12.1  | 52.5 ± 11.8     | 58.9 ± 13.7  | 0.002     | 0.001     | 0.141     |
| BMI (kg/m²)                      | 22.25 ± 3.48 | 23.15 ± 3.67    | 23.62 ± 3.56 | 0.359     | 0.116     | 0.327     |
| Tumor location                   |              |                 |              | 0.645     | > 0.999   | 0.496     |
| Head and Neck                    | 10           | 21              | 4            |           |           |           |
| Body and Tail                    | 11           | 18              | 6            |           |           |           |
| Tumor type                       |              |                 |              | 0.629     | 0.691     | 0.537     |
| Serous cystic tumor              | 7            | 9               | 2            |           |           |           |
| Mucinous cystic tumor            | 3            | 4               | 3            |           |           |           |
| IPMN                             | 4            | 10              | 1            |           |           |           |
| Solid pseudopapillary tumor      | 5            | 7               | 2            |           |           |           |
| Pancreatic neuroendocrine tumor  | 2            | 9               | 2            |           |           |           |
| HbA1c (%)                        | 5.29 ± 0.21  | 5.77 ± 0.32     | 6.65 ± 0.78  | < 0.001   | 0.002     | 0.015     |
| CA19-9 (U/ml)                    | 14.08 ± 14.42| 21.79 ± 46.83   | 16.44 ± 12.25| 0.466     | 0.586     | 0.792     |
| Total bilirubin (μmol/L)         | 14.67 ± 9.03 | 11.74 ± 8.54    | 12.94 ± 5.51 | 0.219     | 0.681     | 0.640     |
| Triglyceride (mmol/L)            | 1.22 ± 0.56  | 1.29 ± 0.66     | 1.34 ± 0.76  | 0.679     | 0.514     | 0.692     |
| Total bile acids (μmol/L)        | 9.3 ± 19.8   | 5.7 ± 5.2       | 5.7 ± 5.4    | 0.279     | 0.674     | 0.824     |
| Pancreatic main duct dilation    |              |                 |              | 0.541     | > 0.999   | 0.709     |
| Tumor volume (cm³)               | 24.28 ± 32.05| 22.89 ± 35.61   | 64.69 ± 74.12| 0.882     | 0.041     | 0.049     |
| Remnant pancreatic volume (cm³)  | 70.48 ± 14.08| 57.44 ± 18.20   | 37.38 ± 20.40| 0.001     | < 0.001   | < 0.001   |

P value 1, NGT and pre-DM; P value 2, NGT and NOD; P value 3, pre-DM and NOD.

PBLMT, pancreatic benign and low-grade malignant tumors; NGT, normal glucose tolerance; pre-DM, prediabetes mellitus; NOD, new-onset diabetes; BMI, body mass index; IPMN, intraductal papillary mucinous tumors; CA19-9, carbohydrate antigen 19-9.

Glucose metabolism in patients with different glucose tolerance statuses.

For β-cell function indices (Table 2), HOMA-β was lower in pre-DM (124.40 ± 62.59) and NOD (76.38 ± 34.57) patients than in NGT patients (134.35 ± 35.48, P = 0.032 and P = 0.001 respectively). In addition, NGT patients had higher levels of IGI (27.44 ± 20.80) than pre-DM (19.09 ± 14.89) and NOD (7.06 ± 8.63) patients (P = 0.041 and P = 0.021 respectively). Similarly, ISSI-2 was lower in pre-DM (8.91 ± 2.98) and NOD (4.26 ± 2.31) patients than in NGT patients (12.30 ± 4.52, P = 0.032 and P = 0.001 respectively). HOMA-β, IGI, and ISSI were further decreased in NOD patients compared with pre-DM patients (P = 0.015, P = 0.001, and P < 0.001, respectively). For insulin sensitivity indices, the HOMA-IR and Matsuda index did not differ among the three groups (all P > 0.05).

Risk factors for PBLMT patients developing dysglycemia

We then classified patients with pre-DM and NOD as dysglycemia groups to assess the risk factors for PBLMT patients developing dysglycemia (Table 3). In univariate analysis, age over 60 years old (P = 0.014, OR = 6.33, 95% CI: 1.45-27.36), tumor volume more than 24.91 cm³ (P = 0.033, OR = 4.35, 95% CI: 1.13-16.85), and RPV less than 49.36 cm³ (P = 0.005, OR = 10.91, 95% CI: 2.06-57.83) were significantly associated with dysglycemia in PBLMT patients. After multivariate analysis, age over 60 years (P = 0.049, OR = 5.76, 95% CI: 1.01-32.92) and RPV less than 49.36 cm³ (P = 0.024, OR = 8.59, 95% CI: 1.34-55.22) were recognized as independent risk factors for dysglycemia.

Correlation between RPV and patient characteristics

The correlation between RPV and the characteristics of PBLMT patients is shown in Figure 2. The analysis of all patients revealed inverse correlations between RPV and both age (r = -0.28, P = 0.019, Figure 2A) and tumor volume (r = -0.28, P = 0.032, Figure 2B). Furthermore, positive correlations were
found both in IGI (r = 0.29, P = 0.019, Figure 2C) and ISSI-2 (r = 0.39, P = 0.0011, Figure 2D).

**Discussion**

In the present prospective observational study, 55.7% and 14.3% of PBLMT patients developed pre-DM and NOD, respectively, before pancreatic surgery. Both were higher than the overall prevalence of DM among adult Chinese individuals (35.7% and 10.9%, respectively) (18). When both fasting plasma glucose (FPG) and 2-hour postprandial plasma glucose were used to detect dysglycemia, the prevalence of NOD in PBLMT patients was comparable to that in PNET patients (9.4%) and IPMN patients (6%) in the previous studies (10, 11). However, the prevalence of pre-DM in our study was more than seven times higher than that previously found in PNET patients (7.1%), which was assessed by preoperative FPG measurement only (10). Indeed, more patients with prediabetes could be ignored by FPG alone than by combined OGTT (19, 20). Therefore, we think our study may reflect the actual dysglycemia status of PBLMT patients.

**TABLE 2** Glucose metabolism indices of PBLMT patients with different glucose tolerance statuses.

| Glucose metabolism indices | NGT (n = 21) | pre-DM (n = 39) | NOD (n = 10) | P value 1 | P value 2 | P value 3 |
|----------------------------|--------------|-----------------|--------------|-----------|-----------|-----------|
| HOMA-β                     | 134.35 ± 35.48 | 124.40 ± 62.59  | 76.38 ± 34.57 | 0.032     | 0.001     | 0.015     |
| HOMA-IR                    | 1.33 ± 0.48   | 1.56 ± 0.72     | 1.31 ± 0.42   | 0.187     | 0.686     | 0.561     |
| Matsuda index (pmol/mmol)  | 137.12 ± 81.09| 103.86 ± 63.87  | 82.42 ± 36.57 | 0.086     | 0.071     | 0.323     |
| IGI (pmol/mmol)            | 27.44 ± 20.80 | 19.09 ± 14.89   | 7.06 ± 8.63   | 0.041     | 0.021     | 0.001     |
| ISSI-2 (pmol/mmol)         | 12.30 ± 4.52  | 8.91 ± 2.98     | 4.26 ± 2.31   | 0.001     | < 0.001   | < 0.001   |

P value 1, NGT and pre-DM; P value 2, NGT and NOD; P value 3, pre-DM and NOD.

**TABLE 3** Univariate and multivariate analysis of the risk factors for PBLMT patients developing dysglycemia.

| Variables          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | P value | OR (95%CI) | P value | OR (95%CI) |
| Sex                | 0.151   | 0.41 (0.12-1.39) | 0.194   | 0.36 (0.08-1.69) |
| Age (year)         |         |             |         |             |
| < 45               | Reference | Reference | Reference | Reference |
| 45-60              | 0.104   | 2.71 (0.81-9.05) | 0.291   | 2.29 (0.49-10.60) |
| > 60               | 0.014   | 6.33 (1.45-27.36) | 0.049   | 5.76 (1.01-32.92) |
| BMI (kg/m²)        |         |             |         |             |
| < 18.5             | Reference | Reference | Reference | Reference |
| 18.5-23.9          | 0.932   | 0.92 (0.15-5.74) | 0.775   | 1.40 (0.14-13.98) |
| > 23.9             | 0.569   | 1.75 (0.26-11.99) | 0.741   | 1.50 (0.14-16.42) |
| Tumor volume (cm³) |         |             |         |             |
| < 4.99             | Reference | Reference | Reference | Reference |
| 4.99-24.91         | 0.108   | 2.75 (0.80-9.75) | 0.419   | 1.91 (0.40-9.24) |
| > 24.91            | 0.033   | 4.35 (1.13-16.85) | 0.099   | 4.15 (0.83-20.77) |
| RPV (cm³)          |         |             |         |             |
| > 71.74            | Reference | Reference | Reference | Reference |
| 49.36-71.74        | 0.091   | 2.81 (0.85-9.28) | 0.114   | 3.52 (0.74-16.73) |
| < 49.36            | 0.005   | 10.91 (2.06-57.83) | 0.024   | 8.59 (1.34-55.22) |

OR, odds ratio; PBLMT, pancreatic benign and low-grade malignant tumors; BMI, body mass index; RPV, Residual pancreatic volume.
alteration in pancreas volume could predict DM. Nevertheless, there are still different views on the compensatory capacity of residual pancreatic parenchyma after partial pancreatectomy. King et al. considered that the loss of pancreatic parenchyma after surgical resection did not affect the endocrine function of the pancreas (26). Shirakawa demonstrated that RPV<56% was an independent risk factor for new postoperative diabetes (27). However, the heterogeneity of the included pathologies in these studies and the lack of observational arms might fail to account for the inherent risk of NOD associated with the underlying disease process. Indeed, our study found that the RPV of PBLMT patients had changed before pancreatic surgery, which was reflected in the progressive decrease in RPV in the NGT, pre-DM, and NOD groups.

Loss of pancreatic parenchyma could directly lead to a decrease in various endocrine cells, thus affecting insulin secretion and glucose metabolism (28). OGTT analysis in our study indicated that abnormal glucose metabolism in patients with PBLMT was positively correlated with a decrease in β-cell function. Indices of insulin sensitivity did not differ among the three groups. In addition, RPV in PBLMT patients was positively correlated with IGI and ISSI-2 in linear regression analysis. Thus, we might claim that the reduced RPV and the consequent reduction in adequate β-cell quantity and insulin secretion increased the risk of dysglycemia in PBLMT patients.

In the present study, by evaluating the various risk factors for pre-DM and NOD, RPV was recognized as one of the significant risk factors by multivariate analysis. The primary question arising from this result is what affected the change in RPVs. Tumors in the pancreas, especially those with large tumor volumes, might physically compress the surrounding normal parenchyma resulting in atrophy. A large tumor volume was observed in the NOD group but was not correlated with dysglycemia in PBLMT patients. Similarly, there is still insufficient evidence to suppose that diabetes secondary to pancreatic cancer is due to local effects of tumor infiltration (29). Although RPV shows a negative correlation with tumor volume, our study proposes that dysglycemia might occur only when the tumor causes a decrease in RPV. Another hypothesis is that pancreatic tumors may obstruct the pancreatic ductal system and induce low-grade pancreatitis distal to the lesion with subsequent parenchymal atrophy and endocrine dysfunction. In a randomized clinical study, Tran K et al. revealed that the incidence of new-onset DM was significantly higher in the pancreatic duct obliteration group (30). However, the presence of pancreatic main duct dilatation did not show a difference between the groups in our study. This may be because tumors in the body and tail of the pancreas accounted for half of the enrolled patients, and the relationship between the degree of pancreatic duct dilatation and RPV needs to be assessed. In addition, considering the potential immunopathogenesis of diabetes mellitus secondary to pancreatic cancer (29), the immune microenvironment in the context of PBLMT needs further investigation. Age over 60 years old was
also an independent risk factor for PBLMT patients developing dysglycemia in the present study. Indeed, RPV negatively correlated with age in PBLMT patients. Research had already found that pancreatic volume decreased with a proportionately high fat content in those over 60 years of age (22). Comprehensive analysis is needed to assess the factors affecting RPV in PBLMT patients.

Clinically, our findings suggest that decisions to treat PBLMT with resection should hinge more on the risk of dysglycemia as well as potential malignancy. Surgery is recommended when the RPV is sufficient. Moreover, these findings advocate that in patients with PBLMT, where partial pancreatectomy is indicated, parenchymal sparing pancreatectomy may benefit from a reduced risk of developing dysglycemia. A nationwide survey showed that in patients with pancreatic body or tail lesions, a significant advantage in preserving endocrine function was found by middle pancreatectomy compared to standard distal pancreatectomy (4).

In conclusion, 70% of PBLMT patients had dysglycemia before pancreatic surgery. Old age and a reduction in RPV were independent risk factors for developing dysglycemia before pancreatic surgery. The decisions to treat PBLMT with surgical resection might hinge more on the risk of dysglycemia as well as potential malignancy.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the West China Hospital of Sichuan University Biomedical Research Ethics Committee (2014 Trail No.37) and conformed to the provisions of the Declaration of Helsinki.

Author contributions

YC designed the study. RW and YL contributed to the interpretation of data and the preparation of the manuscript. JY and JZ performed the data analysis and contributed to the discussion. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Natural Science Foundation of China, No. 82071746; the Key Research and Development Projects in Sichuan Province, No. 2019YFS00043; and the 1·3·5 Project for Disciplines of Excellence–Clinical Research Incubation Project, No. ZY2017302, West China Hospital, Sichuan University.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2022.960843/full#supplementary-material

References

1. Fitzgerald TL, Hickner ZI, Schmitz M, Kort EJ. Changing incidence of pancreatic neoplasms: A 16-year review of statewide tumor registry. Pancreas (2008) 37(2):134–8. doi: 10.1097/MPA.0b013e318163a329
2. Schwber AB, Agarunov E, Broda C, Hur C, Gonda TA. Prevalence, incidence, and risk of progression of asymptomatic pancreatic cysts in Large sample real-world data. Pancreas (2021) 50(9):1287–92. doi: 10.1097/mpa.0000000000001918
3. Horiguchi A, Miyakawa S, Ishihara S, Ito M, Asano Y, Furusawa K, et al. Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors. J Hepatobiliary Pancreat Sci (2010) 17 (6):782–7. doi: 10.1007/s00534-010-0221-4
4. Asano Y, Kato H, Arakawa S, Ito M, Nagakawa T, Nakao A, et al. Clinical outcomes of organ-preserving pancreatectomy for benign or low-grade malignant
pancreatic tumors: A multicenter nationwide survey in Japan. J Hepatobiliary Pancreas Sci (2022) 29(6):896–910. doi: 10.1002/jhp.1154

5. Hardt PD, Brendel MD, Kloer HU, Bretzel RG. Is pancreatic diabetes (type 3c diabetes) underdiagnosed and misdiagnosed? Diabetes Care (2008) 31 Suppl 2: S165–169. doi: 10.2337/dc08-s244

6. Cui Y, Andersen DK. Pancreaticobiliary diabetes: special considerations for management. Pancreatology (2011) 11(3):279–94. doi: 10.1159/000329188

7. Mezza T, Cefalo CMA, Canti F, Quero G, Pontecorvi A, Alfieri S, et al. Endocrine and metabolic insights from pancreatic surgery. Trends Endocrinol Metab (2020) 31(10):760–72. doi: 10.1016/j.tem.2020.07.003

8. De Bruijn KM, van Eijck CH. New-onset diabetes after distal pancreatectomy: A systematic review. Ann Surg (2015) 261(5):854–61. doi: 10.1097/Sla.0000000000001898

9. Beger HG, Posch B, Mayer B, Siech M. New onset of diabetes and pancreatic exocrine insufficiency after pancreaticoduodenectomy for benign and malignant tumors: A systematic review and meta-analysis of long-term results. Ann Surg (2018) 267(2):258–70. doi: 10.1097/Sla.0000000000002422

10. Zhuge X, Wang Y, Chen X, Guo C. Diabetes in patients with pancreatic neuroendocrine neoplasms. Front Endocrinol (2020) 11:615082. doi: 10.3389/fendo.2020.615082

11. Pergolini I, Schorn S, Jäger C, Goß R, Novotny A, Friess H, et al. Diabetes mellitus in intraductal papillary mucinous neoplasms: A systematic review and meta-analysis. Surgery (2021) 169(2):411–8. doi: 10.1016/j.surg.2020.07.006

12. American diabetes association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2018. Diabetes Care (2018) 41(Suppl 1): S13–27. doi: 10.2337/dc18-s002

13. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 28(7):412–9. doi: 10.1007/bf00280883

14. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care (1999) 22(9):1462–70. doi: 10.2337/diacare.22.9.1462

15. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. J Clin Endocrinol Metab (2012) 97(11):E2109–13. doi: 10.1210/jc.2012-1815

16. Williams AJK, Thrower SL, Sequoros IM, Ward A, Bickerton AS, Trayl JM, et al. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab (2012) 97(11):E2109–13. doi: 10.1210/jc.2012-1815

17. Miyamoto R, Oshiro Y, Sano N, Inagawa S, Ohkohchi N. Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resection. Pancreatology (2019) 19(5):716–21. doi: 10.1016/j.pan.2019.05.464

18. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, et al. Prevalence and control of diabetes in Chinese adults. JAMA (2013) 310(9):948–59. doi: 10.1001/jama.2013.168118

19. Aekplakorn W, Tangtayotai V, Numsangkul S, Sripho W, Tatsano N, Burapasiriwat T, et al. Detecting prediabetes and diabetes: Agreement between fasting plasma glucose and oral glucose tolerance test in Thai adults. J Diabetes Res (2015) 2015:396505. doi: 10.1155/2015/396505

20. Menke A, Casagrande S, Cowie CC. Contributions of ATc, fasting plasma glucose, and 2-hour plasma glucose to prediabetes prevalence: NHANES 2011-2014. Ann Epidemiol (2018) 28(10):681–685.e682. doi: 10.1016/j.amepi.2018.07.012

21. Tabak AG, Herder C, Rathmann W, Brunner EJ, Krivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet (2012) 379(9833):2279–90. doi: 10.1016/s0140-6736(12)62083-9

22. Saisho Y, Butler AE, Meier JJ, Monchamp T, Allen-Auerbach M, Rizza RA, et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin Ansat (2007) 20(8):933–42. doi: 10.1002/ca.20543

23. Al-Mrabeh A, Hollingsworth KG, Steven S, Taylor R. Morphology of the pancreas in type 2 diabetes: effect of weight loss with or without normalisation of insulin secretory capacity. Diabetologia (2016) 59(8):1753–9. doi: 10.1007/s00125-016-3984-6

24. Yaghahi S. Diabetes and pancreas size, does it matter? J Diabetes Invest (2017) 8(4):413–5. doi: 10.1111/jdi.12590

25. Martin S, Sorokin EP, Thomas EL, Sattar N, Cule M, Bell JD, et al. Estimating the effect of liver and pancreas volume and fat content on risk of diabetes: A mendelian randomization study. Diabetes Care (2022) 45(2):460–8. doi: 10.2337/dc21-1262

26. King J, Razanjian K, Matsumoto J, Reber HA, Yeh MW, Hines OJ, et al. Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg (2008) 12(9):1548–53. doi: 10.1007/s11605-008-0560-5

27. Shirakawa S, Matsumoto I, Toyama H, Shinzeki M, Akiyoshi T, Fukumoto T, et al. Pancreatic volumetric assessment as a predictor of new-onset diabetes following distal pancreatectomy. J Gastrointest Surg (2012) 16(12):2212–9. doi: 10.1007/s11616-012-2039-7

28. Wynne K, Devereaux B, Dornhorst A. Diabetes of the exocrine pancreas. J Gastroenterol Hepatol (2019) 34(2):346–54. doi: 10.1111/jgh.14451

29. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Foreman CE, et al. Type 3c (pancreaticobiliary) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol (2019) 3(6):226–37. doi: 10.1016/s2468-1253(19)30106-6

30. Tran K, Van Eijck C, Di Carlo V, Hop WC, Zerbib A, Balzano G, et al. Occlusion of the pancreatic duct versus pancreateojejunostomy: A prospective randomized trial. Ann Surg (2002) 236(4):422–8. doi: 10.1097/00000658-200201000-00004